CoChat

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

Open access

The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The cryopyrin-associated periodic syndrome (CAPS) is a rare inherited inflammatory disease associated with overproduction of interleukin-1. Canakinumab is a human anti-interleukin-1beta monoclonal antibody. METHODS: We performed a three-part, 48-week, double-blind, placebo-controlled, randomized withdrawal study of canakinumab in patients with CAPS. In part 1, 35 patients received 150 mg of canakinumab subcutaneously. Those with a complete response to treatment entered part 2 and were randomly assigned to receive either 150 mg of canakinumab or placebo every 8 weeks for up to 24 weeks. After the completion of part 2 or at the time of relapse, whichever occurred first, patients proceeded to part 3 and received at least two more doses of canakinumab. We evaluated therapeutic responses using disease-activity scores and analysis of levels of C-reactive protein (CRP) and serum amyloid A protein (SAA). RESULTS: In part 1 of the study, 34 of the 35 patients (97%) had a complete response to canakinumab. Of these patients, 31 entered part 2, and all 15 patients receiving canakinumab remained in remission. Disease flares occurred in 13 of the 16 patients (81%) receiving placebo (P<0.001). At the end of part 2, median CRP and SAA values were normal (<10 mg per liter for both measures) in patients receiving canakinumab but were elevated in those receiving placebo (P<0.001 and P=0.002, respectively). Of the 31 patients, 28 (90%) completed part 3 in remission. In part 2, the incidence of suspected infections was greater in the canakinumab group than in the placebo group (P=0.03). Two serious adverse events occurred during treatment with canakinumab: one case of urosepsis and an episode of vertigo. CONCLUSIONS: Treatment with subcutaneous canakinumab once every 8 weeks was associated with a rapid remission of symptoms in most patients with CAPS. (ClinicalTrials.gov number, NCT00465985.)

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa0810787

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 5

  1. Muckle TJ, 1962, Q J Med, 31, 235
  2. Lachmann HJ, 2008, Clin Exp Rheumatol, 26, 181
  3. Kuemmerle-Deschner JB, 2008, Clin Exp Rheumatol, 26, 180
  4. Kummerle-Deschner J, 2008, Ann Rheum Dis, 67, 104
  5. Maier J, 2008, J Rheumatol, 35, 939

Cited by

See all 869

Metadata

Authors
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N.
Affiliations
  • University College London (GB)
  • Universitätsklinikum Tübingen (DE)
  • University of California, San Francisco (US)
  • Université de Lille (FR)
  • Hôpital Necker-Enfants Malades (FR)
  • Novartis (Switzerland) (CH)
  • Novartis (United States) (US)
Venue
New England Journal of Medicine
Published
2009-06-04
Volume
360
Issue
23
Pages
2416-2425
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2149374693
Cited by
869
References
19
Citations by year
2026: 23 · 2025: 30 · 2024: 31 · 2023: 23 · 2022: 37 · 2021: 40 · 2020: 53 · 2019: 56 · 2018: 34 · 2017: 38 · 2016: 55 · 2015: 67 · 2014: 50 · 2013: 66 · 2012: 73
FWCI
35.40
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Novartis Pharma
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords
canakinumab, cryopyrin-associated periodic syndromes, IL-1β, interleukin-1 receptor antagonist, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, disease flares, C-reactive protein, serum amyloid A, infection risk, urosepsis, vertigo, treatment withdrawal
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, Adolescent, Adult, Aged, Antibodies, Monoclonal, Carrier Proteins, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Mutation, Familial Mediterranean Fever, Interleukin-1beta, Young Adult, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.